Pacira BioSciences (PCRX) Financials

Pacira BioSciences logo
$36.48 +0.02 (+0.05%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$36.48 +0.01 (+0.01%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Pacira BioSciences

Annual Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1.86 -38 -43 -0.47 -11 146 42 -15 42 -100 7.03
Consolidated Net Income / (Loss)
1.86 -38 -43 -0.47 -11 146 42 32 42 -100 7.03
Net Income / (Loss) Continuing Operations
1.86 -38 -43 -0.47 -11 146 42 -15 42 -100 7.03
Total Pre-Tax Income
2.12 -38 -42 -0.43 -11 20 56 27 62 -63 17
Total Operating Income
9.46 -32 -25 16 10 46 90 60 88 -73 19
Total Gross Profit
177 166 199 250 314 312 401 1,134 490 531 577
Total Revenue
249 276 287 337 421 430 542 1,334 675 701 726
Operating Revenue
249 276 287 337 421 430 542 1,334 675 701 726
Total Cost of Revenue
72 110 88 87 107 117 140 199 185 170 150
Operating Cost of Revenue
72 110 88 87 107 117 140 199 185 170 150
Total Operating Expenses
168 198 224 235 304 266 311 1,061 403 604 557
Selling, General & Admin Expense
139 153 161 177 201 194 199 255 269 294 369
Research & Development Expense
29 46 57 56 72 59 56 85 76 82 117
Amortization Expense
- - 0.00 0.00 5.70 7.87 14 115 57 57 57
Impairment Charge
- - - - - 5.17 - 0.00 0.00 163 0.00
Restructuring Charge
- - 4.87 1.56 25 - - - -0.35 7.70 14
Total Other Income / (Expense), net
-7.34 -5.82 -18 -16 -21 -26 -34 -93 -26 10 -2.32
Interest Expense
7.78 7.06 22 22 24 34 32 40 37 9.05 18
Interest & Investment Income
0.68 1.32 4.08 6.50 7.38 4.63 0.90 4.54 11 20 23
Other Income / (Expense), net
-0.24 -0.08 0.17 -0.89 -4.98 2.85 -2.67 -58 -0.19 -0.37 -6.62
Income Tax Expense
0.26 0.11 0.14 0.05 0.27 -125 14 -5.21 20 36 9.84
Basic Earnings per Share
$0.05 ($1.02) ($1.07) ($0.01) ($0.27) $3.41 $0.95 $0.35 $0.91 ($2.15) $0.16
Weighted Average Basic Shares Outstanding
36.54M 37.24M 39.81M 40.91M 41.51M 42.67M 44.26M 45.52M 46.22M 46.25M 44.57M
Diluted Earnings per Share
$0.04 ($1.02) ($1.07) ($0.01) ($0.27) $3.33 $0.92 $0.34 $0.89 ($2.15) $0.16
Weighted Average Diluted Shares Outstanding
41.30M 37.24M 39.81M 40.91M 41.51M 43.68M 45.63M 46.54M 51.98M 46.25M 45.04M
Weighted Average Basic & Diluted Shares Outstanding
37.10M 37.24M 39.81M 40.91M 41.51M 43.86M 44.85M 45.95M 46.50M 46.28M 40.49M

Quarterly Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
8.98 19 -143 -289 4.81 -4.85 5.43 1.64 2.92 4.65 29
Consolidated Net Income / (Loss)
8.98 19 -143 -84 4.81 -4.85 5.43 1.64 2.92 4.65 29
Net Income / (Loss) Continuing Operations
8.98 19 -143 -289 4.81 -4.85 5.43 1.64 2.92 4.65 29
Total Pre-Tax Income
14 37 -139 -38 8.71 -1.93 9.52 0.57 5.00 2.56 29
Total Operating Income
13 28 -140 25 1.99 8.50 6.36 2.34 6.90 4.27 22
Total Gross Profit
120 134 130 848 135 140 145 157 141 148 139
Total Revenue
167 178 169 888 169 181 180 197 177 192 177
Operating Revenue
167 178 169 888 169 181 180 197 177 192 177
Total Cost of Revenue
47 44 39 40 34 41 34 40 36 44 37
Operating Cost of Revenue
47 44 39 40 34 41 34 40 36 44 37
Total Operating Expenses
106 106 269 1,110 133 132 139 154 134 144 117
Selling, General & Admin Expense
72 68 74 80 87 89 92 102 94 92 84
Research & Development Expense
18 20 19 24 25 28 26 38 28 30 27
Amortization Expense
14 14 14 72 14 14 14 14 14 14 12
Other Operating Expenses / (Income)
- 2.74 - - 6.19 0.63 6.79 - -2.28 7.59 -5.73
Total Other Income / (Expense), net
0.43 8.34 0.67 19 6.72 -10 3.16 -1.77 -1.90 -1.71 6.54
Interest Expense
3.32 -3.63 4.69 -2.84 4.58 4.70 5.26 3.89 3.70 3.62 2.89
Interest & Investment Income
3.90 4.75 5.48 5.56 6.90 5.01 8.53 2.30 1.93 1.94 2.50
Other Income / (Expense), net
-0.16 -0.04 -0.12 10 4.40 -11 -0.11 -0.17 -0.14 -0.03 6.93
Income Tax Expense
4.66 18 4.61 46 3.89 2.92 4.09 -1.07 2.08 -2.10 0.29
Basic Earnings per Share
$0.19 $0.41 ($3.11) $0.36 $0.10 ($0.11) $0.12 $0.05 $0.07 $0.12 $0.72
Weighted Average Basic Shares Outstanding
46.50M 46.17M 46.13M 46.25M 46.28M 45.46M 44.04M 44.57M 40.46M 39.46M 39.86M
Diluted Earnings per Share
$0.19 $0.39 ($3.11) $0.38 $0.10 ($0.11) $0.12 $0.05 $0.07 $0.12 $0.70
Weighted Average Diluted Shares Outstanding
52.19M 50.54M 46.13M 46.25M 46.53M 45.46M 44.46M 45.04M 40.91M 40.30M 40.83M
Weighted Average Basic & Diluted Shares Outstanding
46.55M 46.13M 46.17M 46.28M 46.30M 44.93M 43.02M 40.49M 39.35M 39.86M 40.09M

Annual Cash Flow Statements for Pacira BioSciences

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
19 -21 18 78 -54 22 486 -481 49 123 -118
Net Cash From Operating Activities
28 33 18 49 71 77 126 145 155 189 152
Net Cash From Continuing Operating Activities
28 33 18 49 71 77 126 145 155 189 152
Net Income / (Loss) Continuing Operations
1.86 -38 -43 -0.47 -11 146 42 16 42 -100 7.03
Consolidated Net Income / (Loss)
1.86 -38 -43 -0.47 -11 146 42 16 42 -100 7.03
Depreciation Expense
11 13 14 13 20 20 29 92 76 79 91
Amortization Expense
4.58 4.57 12 13 15 18 26 7.21 -0.83 -4.20 -1.93
Non-Cash Adjustments To Reconcile Net Income
33 32 37 34 39 41 45 85 67 209 90
Changes in Operating Assets and Liabilities, net
-23 22 -2.57 -11 7.90 -147 -16 -54 -29 5.07 -34
Net Cash From Investing Activities
-19 -62 -224 21 -128 -278 -21 -225 78 -83 99
Net Cash From Continuing Investing Activities
-19 -62 -224 21 -128 -278 -21 -225 78 -83 99
Purchase of Property, Plant & Equipment
-40 -25 -19 -15 -10 -38 -46 -30 -15 -11 -15
Acquisitions
0.00 0.00 -15 0.00 -118 0.00 -420 - 0.00 0.00 -17
Purchase of Investments
-189 -193 -503 -363 -320 -548 -629 -401 -144 -252 -142
Sale and/or Maturity of Investments
217 172 322 405 319 308 1,078 238 237 180 274
Net Cash From Financing Activities
11 7.26 224 8.95 3.67 222 381 -402 -183 17 -370
Net Cash From Continuing Financing Activities
11 7.26 224 8.95 3.67 222 381 -402 -183 17 -370
Repayment of Debt
-1.47 0.00 -129 0.00 -0.34 -189 0.00 -428 -336 -211 -318
Repurchase of Common Equity
- - - - - - -4.55 -1.18 -1.16 -34 -151
Issuance of Debt
0.00 0.00 345 0.00 0.00 369 364 0.00 150 288 101
Issuance of Common Equity
2.09 1.50 1.86 1.78 2.40 2.55 2.81 2.95 2.81 2.30 2.80
Other Financing Activities, net
10 5.77 6.49 7.17 1.61 40 19 24 1.83 -27 -5.12
Effect of Exchange Rate Changes
- - - - - - - - 0.00 0.00 -0.08
Cash Interest Paid
4.22 3.85 6.90 8.21 8.20 7.21 7.00 33 28 15 15

Quarterly Cash Flow Statements for Pacira BioSciences

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
31 63 -1.09 31 6.84 17 -153 11 -14 62 41
Net Cash From Operating Activities
49 53 54 33 35 12 61 44 26 57 50
Net Cash From Continuing Operating Activities
49 53 54 33 35 12 61 44 26 57 50
Net Income / (Loss) Continuing Operations
8.98 19 -143 16 4.81 -4.85 5.43 1.64 2.92 4.65 29
Consolidated Net Income / (Loss)
8.98 19 -143 16 4.81 -4.85 5.43 1.64 2.92 4.65 29
Depreciation Expense
18 19 20 21 21 27 21 21 21 21 19
Amortization Expense
0.71 0.79 0.86 0.87 -1.04 0.87 0.68 -4.35 0.01 0.88 0.43
Non-Cash Adjustments To Reconcile Net Income
13 5.04 176 15 8.67 26 41 14 14 15 5.21
Changes in Operating Assets and Liabilities, net
7.77 9.66 -0.04 -20 1.86 -38 -7.30 11 -12 16 -3.36
Net Cash From Investing Activities
-16 -15 -52 -0.37 -26 62 44 19 19 12 61
Net Cash From Continuing Investing Activities
-16 -15 -52 -0.37 -26 62 44 19 19 12 61
Purchase of Property, Plant & Equipment
-2.84 -1.59 -4.09 -2.12 -8.55 -2.70 -3.87 -0.22 -2.72 -1.34 -3.63
Acquisitions
0.00 - - - -17 - - - -0.34 - -6.00
Purchase of Investments
-56 -50 -101 -45 -70 -6.31 -39 -28 0.00 -3.91 -27
Sale and/or Maturity of Investments
43 36 53 47 69 71 86 47 23 17 24
Net Cash From Financing Activities
-2.82 25 -2.85 -1.96 -2.99 -58 -257 -52 -59 -7.65 -70
Net Cash From Continuing Financing Activities
-2.82 25 -2.85 -1.96 -2.99 -58 -257 -52 -59 -7.65 -70
Repayment of Debt
-2.81 -202 -2.81 -2.81 -2.81 -3.75 -306 -5.00 -5.00 -5.00 -70
Other Financing Activities, net
-0.00 -27 -0.03 -0.08 -0.18 -5.29 0.00 0.35 -4.35 -3.04 0.23
Effect of Exchange Rate Changes
- - - - 0.00 - 0.13 -0.41 0.04 - -0.03
Cash Interest Paid
3.97 3.02 3.20 5.23 2.72 4.97 2.70 4.85 1.60 4.58 0.84
Cash Income Taxes Paid
-0.25 4.91 4.91 1.45 0.29 7.95 0.71 - 0.05 0.86 0.30

Annual Balance Sheets for Pacira BioSciences

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
388 391 628 689 831 1,275 2,075 1,681 1,574 1,554 1,265
Total Current Assets
253 243 391 478 409 652 866 498 510 745 548
Cash & Equivalents
57 36 54 133 78 100 586 104 153 277 159
Short-Term Investments
102 137 257 251 214 422 71 185 125 208 80
Accounts Receivable
26 30 32 38 48 53 96 98 106 113 124
Inventories, net
62 31 41 49 58 65 99 96 104 125 153
Prepaid Expenses
6.12 9.28 6.69 7.95 11 12 15 15 22 22 33
Plant, Property, & Equipment, net
90 101 107 109 105 137 188 184 174 167 141
Total Noncurrent Assets
45 47 130 103 318 486 1,021 999 890 641 576
Long-Term Investments
13 0.00 74 41 65 95 22 64 38 36 22
Goodwill
31 47 55 62 100 100 145 163 163 0.00 20
Intangible Assets
0.08 - - 0.00 104 97 624 541 483 426 368
Noncurrent Deferred & Refundable Income Taxes
- - - - 0.00 106 153 160 144 130 124
Other Noncurrent Operating Assets
0.41 0.62 0.83 0.00 49 89 76 71 61 49 42
Total Liabilities & Shareholders' Equity
388 391 628 689 831 1,275 2,075 1,681 1,574 1,554 1,265
Total Liabilities
169 172 349 368 476 655 1,345 906 704 775 572
Total Current Liabilities
150 45 56 61 108 253 521 148 97 310 121
Accounts Payable
8.74 7.51 15 14 13 10 11 15 16 19 15
Accrued Expenses
35 37 41 46 70 71 128 90 64 80 96
Other Current Liabilities
- - - 0.00 23 22 7.89 9.12 8.80 8.89 9.84
Total Noncurrent Liabilities
20 128 293 307 368 401 824 758 607 465 451
Long-Term Debt
0.00 109 276 291 306 313 675 656 514 384 372
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - - - - 0.00 4.21
Other Noncurrent Operating Liabilities
11 19 16 17 62 88 149 103 93 82 75
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
218 219 279 321 355 620 730 775 870 778 693
Total Preferred & Common Equity
218 219 279 321 355 620 730 775 870 778 693
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
218 219 279 321 355 620 730 775 870 778 693
Common Stock
527 565 669 710 754 873 942 924 977 1,009 1,065
Retained Earnings
-308 -346 -389 -388 -399 -254 -212 -149 -107 -206 -199
Treasury Stock
- - - - - - - - 0.00 -25 -177
Accumulated Other Comprehensive Income / (Loss)
-0.05 -0.03 -0.45 -0.28 0.32 0.32 0.17 -0.38 0.25 0.34 4.33

Quarterly Balance Sheets for Pacira BioSciences

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
1,542 1,534 1,583 1,647 1,522 1,587 1,537 1,298 1,209 1,244 1,203
Total Current Assets
429 447 543 632 690 760 746 563 515 615 590
Cash & Equivalents
87 99 184 247 246 284 300 148 144 206 247
Short-Term Investments
134 136 142 157 208 210 145 99 58 45 49
Accounts Receivable
99 97 102 105 101 105 114 115 126 132 123
Inventories, net
92 97 97 103 112 134 148 158 150 135 129
Prepaid Expenses
17 19 19 20 24 28 37 43 37 30 42
Plant, Property, & Equipment, net
180 176 172 169 167 164 155 147 136 130 129
Total Noncurrent Assets
933 911 868 846 665 662 636 587 557 498 483
Long-Term Investments
36 36 37 36 37 28 19 20 23 24 23
Goodwill
163 163 163 163 0.00 22 20 20 20 20 20
Intangible Assets
512 498 469 455 440 435 423 382 353 285 273
Noncurrent Deferred & Refundable Income Taxes
156 152 141 135 134 129 128 120 122 125 125
Other Noncurrent Operating Assets
66 63 59 56 54 49 47 44 39 45 42
Total Liabilities & Shareholders' Equity
1,542 1,534 1,583 1,647 1,522 1,587 1,537 1,298 1,209 1,244 1,203
Total Liabilities
734 703 691 768 772 788 779 570 555 572 490
Total Current Liabilities
109 94 93 93 306 315 313 107 109 122 126
Accounts Payable
24 17 8.98 19 19 23 30 18 14 18 18
Accrued Expenses
56 60 67 65 76 80 71 80 85 93 99
Other Current Liabilities
8.98 8.63 9.00 9.15 9.19 9.41 9.62 9.75 9.82 10 10
Total Noncurrent Liabilities
625 609 598 675 466 473 466 463 446 450 364
Long-Term Debt
532 516 512 589 386 381 378 377 368 363 294
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - 7.00 4.58 4.59 4.09 4.07 4.03
Other Noncurrent Operating Liabilities
93 93 86 86 80 85 84 82 74 83 67
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
808 832 892 879 750 799 758 727 654 672 712
Total Preferred & Common Equity
808 832 892 879 750 799 758 727 654 672 712
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
808 832 892 879 750 799 758 727 654 672 712
Common Stock
951 963 990 983 996 1,024 1,036 1,050 1,074 1,088 1,100
Retained Earnings
-143 -132 -98 -79 -222 -202 -206 -201 -196 -192 -163
Treasury Stock
- - - -25 -25 -25 -76 -126 -227 -227 -227
Accumulated Other Comprehensive Income / (Loss)
-0.17 -0.01 0.15 0.11 0.68 1.35 4.06 4.12 3.46 3.24 3.01

Annual Metrics And Ratios for Pacira BioSciences

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - - - - - - 43,021,275.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 43,021,275.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 0.16
Growth Metrics
- - - - - - - - - - -
Revenue Growth
25.97% 10.99% 3.71% 17.67% 24.83% 2.05% 26.04% 146.27% 1.22% 3.85% 3.63%
EBITDA Growth
180.42% -157.84% 105.02% 5,484.60% -1.12% 115.54% 62.21% -28.92% 39.83% -86.84% 11,974.11%
EBIT Growth
263.25% -448.26% 22.85% 160.67% -63.37% 793.93% 77.35% -97.69% 2,954.37% -203.19% 117.05%
NOPAT Growth
328.95% -370.81% 22.13% 163.82% -34.15% 4,476.82% -80.07% 7.26% -16.95% -186.15% 115.58%
Net Income Growth
113.53% -2,144.67% -12.28% 98.89% -2,238.85% 1,421.01% -71.15% -24.21% 163.72% -337.30% 107.07%
EPS Growth
110.26% -2,650.00% -4.90% 99.07% -2,600.00% 1,333.33% -72.37% -63.04% 161.76% -341.57% 107.44%
Operating Cash Flow Growth
5.48% 19.39% -46.84% 174.78% 44.30% 9.23% 63.20% 15.56% 6.45% 22.46% -19.75%
Free Cash Flow Firm Growth
-73.66% 45.03% -19.07% 80.33% -1,588.67% 260.50% -425.64% 110.82% 55.15% 89.20% -74.09%
Invested Capital Growth
63.68% 3.41% 9.88% 10.32% 61.81% 52.92% 136.70% 0.93% -3.23% -21.58% -4.60%
Revenue Q/Q Growth
3.12% 1.31% 2.20% 4.99% 6.94% 2.03% 5.50% 0.00% 102.79% 101.73% -48.76%
EBITDA Q/Q Growth
-24.91% -11.42% 105.67% 7.00% -17.14% 26.57% -4.35% 0.00% 3.05% 28.86% -27.14%
EBIT Q/Q Growth
-48.78% -5.38% 30.75% 31.61% -67.21% 59.09% -14.60% 0.00% 39.83% 1.91% -72.26%
NOPAT Q/Q Growth
-52.05% -5.43% 30.47% 31.34% -81.95% -64.95% -21.74% 0.00% 89.70% -13.04% -72.50%
Net Income Q/Q Growth
-81.73% -4.04% 16.74% 88.68% -610.71% 15.38% -31.88% 0.00% 1,101.63% -119.46% 109.00%
EPS Q/Q Growth
-85.71% -5.15% 18.94% 88.89% -640.00% 16.84% -34.75% 0.00% 641.67% -10.26% -67.35%
Operating Cash Flow Q/Q Growth
8.82% 1.07% -2.30% 9.62% 7.11% 36.90% -15.72% 0.00% 3.72% -7.09% 7.46%
Free Cash Flow Firm Q/Q Growth
2.28% 14.73% -19.30% 60.93% -51.46% -77.98% -1,397.82% -87.85% 109.06% -6.61% 22.73%
Invested Capital Q/Q Growth
0.30% -3.40% 4.59% 0.05% 1.26% 0.06% 117.36% 0.00% -0.91% -0.35% -3.91%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
71.15% 60.16% 69.33% 74.25% 74.65% 72.69% 74.10% 85.06% 86.32% 87.84% 79.39%
EBITDA Margin
10.15% -5.29% 0.26% 12.15% 9.63% 20.33% 26.17% 7.55% 10.43% 1.32% 14.00%
Operating Margin
3.80% -11.59% -8.70% 4.72% 2.49% 10.79% 16.61% 4.50% 6.49% -5.23% 2.64%
EBIT Margin
3.70% -11.62% -8.64% 4.46% 1.31% 11.45% 16.11% 0.15% 4.56% -4.53% 1.73%
Profit (Net Income) Margin
0.75% -13.73% -14.87% -0.14% -2.62% 33.87% 7.75% 2.39% 6.22% -14.20% 0.97%
Tax Burden Percent
87.55% 100.28% 100.33% 110.82% 102.49% 724.39% 74.43% 119.60% 68.00% 157.77% 41.69%
Interest Burden Percent
23.00% 117.87% 171.46% -2.83% -195.28% 40.83% 64.64% 1,320.95% 200.60% 198.82% 134.23%
Effective Tax Rate
12.45% 0.00% 0.00% 0.00% 0.00% -624.39% 25.57% -19.60% 32.00% 0.00% 58.31%
Return on Invested Capital (ROIC)
6.85% -14.69% -10.72% 6.22% 2.98% 87.27% 8.55% 6.49% 5.45% -5.35% 0.97%
ROIC Less NNEP Spread (ROIC-NNEP)
15.54% 8.80% 18.37% 15.80% 22.94% 272.73% -14.51% -4.81% 14.42% -114.62% -0.12%
Return on Net Nonoperating Assets (RNNOA)
-5.90% -2.66% -6.37% -6.37% -6.24% -57.41% -2.33% -2.26% 4.75% -18.81% -0.01%
Return on Equity (ROE)
0.95% -17.35% -17.10% -0.16% -3.26% 29.86% 6.22% 4.23% 10.20% -24.16% 0.96%
Cash Return on Invested Capital (CROIC)
-41.45% -18.04% -20.14% -3.60% -44.23% 45.42% -72.66% 5.57% 8.74% 18.84% 5.68%
Operating Return on Assets (OROA)
2.58% -8.24% -4.86% 2.28% 0.72% 4.67% 5.21% 0.11% 3.78% -4.06% 0.89%
Return on Assets (ROA)
0.52% -9.74% -8.36% -0.07% -1.45% 13.82% 2.51% 1.69% 5.15% -12.73% 0.50%
Return on Common Equity (ROCE)
0.95% -17.35% -17.10% -0.16% -3.26% 29.86% 6.22% 4.23% 10.20% -24.16% 0.96%
Return on Equity Simple (ROE_SIMPLE)
0.85% -17.33% -15.25% -0.15% -3.10% 23.48% 5.75% 4.11% 9.64% -25.58% 0.00%
Net Operating Profit after Tax (NOPAT)
8.28 -22 -17 11 7.34 336 67 72 60 -51 8.00
NOPAT Margin
3.32% -8.11% -6.09% 3.30% 1.74% 78.15% 12.36% 5.38% 4.42% -3.66% 1.10%
Net Nonoperating Expense Percent (NNEP)
-8.68% -23.49% -29.10% -9.59% -19.96% -185.46% 23.06% 11.30% -8.97% 109.27% 1.09%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 4.90% 4.28% -3.77% 0.75%
Cost of Revenue to Revenue
28.85% 39.84% 30.67% 25.75% 25.35% 27.31% 25.90% 14.94% 13.68% 12.16% 20.61%
SG&A Expenses to Revenue
55.84% 55.22% 56.34% 52.56% 47.69% 45.04% 36.81% 19.08% 19.96% 20.98% 50.76%
R&D to Revenue
11.51% 16.53% 19.99% 16.51% 17.13% 13.83% 10.26% 6.36% 5.65% 5.82% 16.15%
Operating Expenses to Revenue
67.35% 71.75% 78.03% 69.53% 72.17% 61.90% 57.49% 79.53% 77.60% 113.49% 76.74%
Earnings before Interest and Taxes (EBIT)
9.22 -32 -25 15 5.50 49 87 2.01 62 -63 13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
25 -15 0.73 41 41 87 142 101 141 19 102
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
12.92 5.52 6.63 5.51 5.33 4.20 3.67 2.28 1.80 1.12 1.61
Price to Tangible Book Value (P/TBV)
15.06 7.01 8.26 6.82 12.52 6.14 0.00 24.84 7.01 2.47 3.65
Price to Revenue (P/Rev)
11.34 4.37 6.46 5.24 4.49 6.05 4.95 1.33 1.16 0.62 1.53
Price to Earnings (P/E)
1,520.80 0.00 0.00 0.00 0.00 17.86 63.85 0.00 167.68 0.00 158.29
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.07% 0.00% 0.00% 0.00% 0.00% 5.60% 1.57% 0.00% 0.60% 0.00% 0.63%
Enterprise Value to Invested Capital (EV/IC)
18.36 7.38 10.23 8.70 6.05 5.26 2.77 1.89 1.65 1.11 1.52
Enterprise Value to Revenue (EV/Rev)
11.06 4.14 6.08 4.85 4.37 5.69 5.63 1.58 1.31 0.67 1.69
Enterprise Value to EBITDA (EV/EBITDA)
108.96 0.00 2,374.63 39.90 45.39 27.99 21.53 20.91 12.58 50.46 12.05
Enterprise Value to EBIT (EV/EBIT)
298.75 0.00 0.00 108.84 334.25 49.70 34.97 1,045.54 28.81 0.00 97.43
Enterprise Value to NOPAT (EV/NOPAT)
332.73 0.00 0.00 146.81 250.78 7.28 45.59 29.33 29.73 0.00 153.11
Enterprise Value to Operating Cash Flow (EV/OCF)
98.29 34.20 98.00 33.47 26.09 31.74 24.27 14.49 11.46 4.94 8.06
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 13.99 0.00 34.20 18.55 5.17 26.15
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.48 0.50 0.99 0.91 0.86 0.75 1.44 0.89 0.60 0.75 0.54
Long-Term Debt to Equity
0.00 0.50 0.99 0.90 0.86 0.51 0.92 0.85 0.59 0.49 0.54
Financial Leverage
-0.38 -0.30 -0.35 -0.40 -0.27 -0.21 0.16 0.47 0.33 0.16 0.12
Leverage Ratio
1.83 1.78 2.05 2.19 2.25 2.16 2.48 2.50 1.98 1.90 1.92
Compound Leverage Factor
0.42 2.10 3.51 -0.06 -4.39 0.88 1.60 32.96 3.97 3.77 2.57
Debt to Total Capital
32.27% 33.18% 49.73% 47.53% 46.30% 42.75% 58.96% 47.08% 37.52% 42.92% 34.94%
Short-Term Debt to Total Capital
32.27% 0.00% 0.06% 0.06% 0.00% 13.83% 21.05% 2.30% 0.62% 14.80% 0.00%
Long-Term Debt to Total Capital
0.00% 33.18% 49.67% 47.47% 46.30% 28.92% 37.90% 44.78% 36.90% 28.13% 34.94%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
67.73% 66.82% 50.27% 52.47% 53.70% 57.25% 41.04% 52.92% 62.48% 57.08% 65.06%
Debt to EBITDA
4.12 -7.44 376.70 7.10 7.55 5.30 7.40 6.85 3.71 31.59 3.66
Net Debt to EBITDA
-2.71 4.37 -148.56 -3.25 -1.25 -1.77 2.62 3.34 1.46 3.51 1.10
Long-Term Debt to EBITDA
0.00 -7.44 376.26 7.09 7.55 3.58 4.76 6.51 3.65 20.70 3.66
Debt to NOPAT
12.57 -4.85 -15.84 26.11 41.72 1.38 15.68 9.60 8.76 -11.40 46.52
Net Debt to NOPAT
-8.26 2.85 6.25 -11.96 -6.91 -0.46 5.54 4.69 3.45 -1.27 13.93
Long-Term Debt to NOPAT
0.00 -4.85 -15.82 26.08 41.72 0.93 10.08 9.14 8.62 -7.47 46.52
Altman Z-Score
9.93 4.01 3.28 3.38 2.67 2.94 1.65 2.10 2.54 1.59 1.96
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.69 5.42 6.96 7.88 3.79 2.57 1.66 3.37 5.24 2.40 4.54
Quick Ratio
1.23 4.52 6.10 6.95 3.15 2.27 1.44 2.62 3.94 1.93 3.01
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-50 -28 -33 -6.45 -109 175 -569 62 96 181 47
Operating Cash Flow to CapEx
69.54% 135.39% 92.31% 336.71% 694.16% 203.78% 274.10% 483.02% 1,020.04% 1,780.64% 991.29%
Free Cash Flow to Firm to Interest Expense
-6.44 -3.90 -1.51 -0.29 -4.61 5.18 -17.92 1.54 1.76 117.91 2.54
Operating Cash Flow to Interest Expense
3.60 4.74 0.82 2.23 2.98 2.28 3.96 3.63 2.86 123.54 8.25
Operating Cash Flow Less CapEx to Interest Expense
-1.58 1.24 -0.07 1.57 2.55 1.16 2.52 2.88 2.58 116.60 7.42
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.70 0.71 0.56 0.51 0.55 0.41 0.32 0.71 0.83 0.90 0.52
Accounts Receivable Turnover
10.33 9.91 9.31 9.68 9.85 8.54 7.25 13.70 13.24 12.81 6.12
Inventory Turnover
1.58 2.37 2.42 1.93 2.00 1.91 1.72 2.05 1.84 1.48 1.08
Fixed Asset Turnover
3.30 2.89 2.76 3.13 3.95 3.56 3.33 7.17 7.55 8.22 4.72
Accounts Payable Turnover
9.27 13.55 7.93 5.98 7.86 10.10 13.37 15.47 11.95 9.79 8.74
Days Sales Outstanding (DSO)
35.34 36.84 39.22 37.69 37.07 42.72 50.34 26.65 27.57 28.49 59.64
Days Inventory Outstanding (DIO)
230.95 154.02 150.89 189.09 182.76 191.24 212.36 178.21 198.06 245.90 338.98
Days Payable Outstanding (DPO)
39.37 26.93 46.02 61.00 46.46 36.13 27.29 23.59 30.55 37.30 41.78
Cash Conversion Cycle (CCC)
226.92 163.93 144.09 165.78 173.37 197.83 235.40 181.27 195.08 237.09 356.83
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
150 155 170 188 304 465 1,101 1,111 1,076 843 805
Invested Capital Turnover
2.06 1.81 1.76 1.88 1.71 1.12 0.69 1.21 1.23 1.46 0.88
Increase / (Decrease) in Invested Capital
58 5.11 15 18 116 161 636 10 -36 -232 -39
Enterprise Value (EV)
2,754 1,144 1,743 1,636 1,840 2,445 3,051 2,106 1,772 935 1,225
Market Capitalization
2,823 1,208 1,852 1,769 1,890 2,600 2,680 1,769 1,567 870 1,113
Book Value per Share
$5.94 $5.85 $6.89 $7.81 $8.51 $14.26 $16.40 $17.03 $18.74 $16.86 $16.11
Tangible Book Value per Share
$5.10 $4.61 $5.53 $6.30 $3.62 $9.75 ($0.87) $1.56 $4.82 $7.63 $7.08
Total Capital
322 328 556 612 661 1,082 1,780 1,464 1,393 1,364 1,065
Total Debt
104 109 276 291 306 463 1,049 689 522 585 372
Total Long-Term Debt
0.00 109 276 291 306 313 675 656 514 384 372
Net Debt
-68 -64 -109 -133 -51 -154 371 336 205 65 111
Capital Expenditures (CapEx)
40 25 19 15 10 38 46 30 15 11 15
Debt-free, Cash-free Net Working Capital (DFCFNWC)
48 26 24 34 8.93 26 63 96 143 152 189
Debt-free Net Working Capital (DFNWC)
207 198 335 418 301 548 720 384 421 637 427
Net Working Capital (NWC)
103 198 335 417 301 398 345 351 413 435 427
Net Nonoperating Expense (NNE)
6.42 16 25 12 18 190 25 40 -24 148 0.97
Net Nonoperating Obligations (NNO)
-68 -64 -109 -133 -51 -154 371 336 205 65 111
Total Depreciation and Amortization (D&A)
16 17 26 26 35 38 54 99 79 82 89
Debt-free, Cash-free Net Working Capital to Revenue
19.22% 9.28% 8.33% 10.14% 2.12% 6.12% 11.67% 7.17% 10.57% 10.87% 26.01%
Debt-free Net Working Capital to Revenue
83.07% 71.73% 116.95% 123.83% 71.46% 127.53% 132.89% 28.81% 31.20% 45.44% 58.84%
Net Working Capital to Revenue
41.28% 71.73% 116.84% 123.73% 71.46% 92.70% 63.70% 26.29% 30.56% 31.04% 58.84%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.05 ($1.02) ($1.07) ($0.01) ($0.27) $3.41 $0.95 $0.35 $0.91 ($2.15) $0.16
Adjusted Weighted Average Basic Shares Outstanding
36.54M 37.24M 39.81M 41.23M 42.03M 42.67M 44.26M 45.52M 46.22M 46.25M 44.57M
Adjusted Diluted Earnings per Share
$0.04 ($1.02) ($1.07) ($0.01) ($0.27) $3.33 $0.92 $0.34 $0.89 ($2.15) $0.16
Adjusted Weighted Average Diluted Shares Outstanding
41.30M 37.24M 39.81M 41.23M 42.03M 43.68M 45.63M 46.54M 51.98M 46.25M 45.04M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.01) ($0.27) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
37.05M 37.53M 40.71M 40.91M 41.51M 43.86M 44.85M 45.95M 46.50M 46.28M 40.49M
Normalized Net Operating Profit after Tax (NOPAT)
8.28 -22 -14 12 25 36 67 42 60 177 23
Normalized NOPAT Margin
3.32% -8.11% -4.90% 3.63% 5.94% 8.39% 12.36% 3.15% 4.42% 12.64% 3.21%
Pre Tax Income Margin
0.85% -13.69% -14.82% -0.13% -2.55% 4.68% 10.42% 1.99% 9.14% -9.00% 2.32%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
1.19 -4.55 -1.14 0.68 0.23 1.46 2.75 0.05 1.14 -41.41 0.68
NOPAT to Interest Expense
1.06 -3.17 -0.80 0.51 0.31 9.95 2.11 1.80 1.10 -33.50 0.43
EBIT Less CapEx to Interest Expense
-4.00 -8.05 -2.02 0.02 -0.20 0.34 1.30 -0.70 0.86 -48.35 -0.15
NOPAT Less CapEx to Interest Expense
-4.12 -6.67 -1.69 -0.15 -0.12 8.83 0.66 1.04 0.82 -40.44 -0.40
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.83% 3.69% 1.39% -17.25% 2,139.81%

Quarterly Metrics And Ratios for Pacira BioSciences

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - 43,021,275.00 40,489,894.00 39,347,924.00 39,861,886.00
DEI Adjusted Shares Outstanding
- - - - - - - 43,021,275.00 40,489,894.00 39,347,924.00 39,861,886.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - 0.04 0.07 0.12 0.72
Growth Metrics
- - - - - - - - - - -
Revenue Growth
4.23% 5.05% 2.83% 3.74% 1.08% 1.73% 6.49% 5.14% 5.00% 6.24% -1.59%
EBITDA Growth
77.68% -19.42% -425.28% 111.97% -11.68% -45.76% 123.73% -51.30% 5.99% 7.34% 78.31%
EBIT Growth
520.93% -28.80% -907.27% 352.93% -51.04% -107.94% 104.48% -91.21% 5.88% 288.97% 367.11%
NOPAT Growth
501.96% -46.28% -942.66% -25.55% -87.35% -59.19% 103.72% -56.79% 266.11% 30.62% 507.56%
Net Income Growth
145.96% -26.69% -1,421.29% -224.98% -46.41% -125.66% 103.79% -89.79% -39.40% 196.00% 425.06%
EPS Growth
144.19% -23.53% -1,452.17% -34.48% -47.37% -128.21% 103.86% -86.84% -30.00% 209.09% 483.33%
Operating Cash Flow Growth
156.70% 22.38% 21.34% -30.37% -27.78% -77.44% 12.82% 31.86% -27.58% 378.36% -17.69%
Free Cash Flow Firm Growth
2,839.88% 7.20% 113.16% 321.65% 94.45% 78.03% -91.01% -81.61% -64.54% 17.19% 1,253.87%
Invested Capital Growth
-7.85% -6.84% -22.02% -21.58% -18.08% -15.01% -1.07% -4.60% -7.40% -20.60% -17.91%
Revenue Q/Q Growth
-80.48% 6.53% -5.31% 426.90% -80.98% 7.21% -0.87% 9.67% -9.90% 8.47% -8.18%
EBITDA Q/Q Growth
19.63% 48.68% -347.72% 148.11% -50.15% -8.70% 8.36% -31.88% 46.69% -6.03% 85.16%
EBIT Q/Q Growth
69.32% 116.05% -595.19% 125.00% -81.70% -135.05% 379.11% -65.32% 212.13% -37.45% 589.91%
NOPAT Q/Q Growth
-62.56% 67.62% -769.95% 117.71% -93.64% 440.89% -39.01% 84.88% -39.97% 92.97% 183.70%
Net Income Q/Q Growth
-86.56% 110.34% -859.64% 41.78% 105.76% -200.73% 212.07% -69.86% 78.13% 59.57% 512.96%
EPS Q/Q Growth
-67.24% 105.26% -897.44% 112.22% -73.68% -210.00% 209.09% -58.33% 40.00% 71.43% 483.33%
Operating Cash Flow Q/Q Growth
3.19% 8.42% 1.28% -38.55% 7.02% -66.12% 406.44% -28.18% -41.22% 123.75% -12.86%
Free Cash Flow Firm Q/Q Growth
65.96% -8.33% 57.03% 76.48% -23.46% -16.07% -92.07% 258.55% 48.61% 177.40% -8.41%
Invested Capital Q/Q Growth
-2.37% -2.11% -17.65% -0.35% 2.00% 1.55% -4.15% -3.91% -0.99% -12.93% -0.89%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
71.63% 75.14% 76.95% 95.51% 79.69% 77.43% 80.91% 79.53% 79.47% 77.05% 78.92%
EBITDA Margin
19.26% 26.88% -70.32% 6.42% 16.83% 14.33% 15.67% 9.73% 15.84% 13.73% 27.68%
Operating Margin
7.91% 15.86% -82.77% 2.78% 1.18% 4.69% 3.54% 1.19% 3.89% 2.22% 12.61%
EBIT Margin
7.81% 15.84% -82.84% 3.93% 3.78% -1.24% 3.48% 1.10% 3.82% 2.20% 16.53%
Profit (Net Income) Margin
5.37% 10.61% -85.11% -9.40% 2.85% -2.68% 3.03% 0.83% 1.64% 2.42% 16.15%
Tax Burden Percent
65.83% 51.62% 103.32% 222.24% 55.27% 251.53% 57.03% 286.69% 58.34% 182.11% 98.98%
Interest Burden Percent
104.50% 129.73% 99.43% -107.63% 136.22% 86.03% 152.34% 26.34% 73.86% 60.36% 98.66%
Effective Tax Rate
34.17% 48.38% 0.00% 0.00% 44.73% 0.00% 42.97% -186.69% 41.66% -82.11% 1.02%
Return on Invested Capital (ROIC)
6.45% 5.31% -41.69% 2.84% 0.96% 4.86% 3.40% 3.00% 2.01% 3.85% 12.17%
ROIC Less NNEP Spread (ROIC-NNEP)
6.56% 7.25% -67.81% -71.71% 4.34% -3.31% 5.15% -2.74% 0.93% -0.69% 27.37%
Return on Net Nonoperating Assets (RNNOA)
2.09% 1.91% -15.04% -11.76% 0.56% -0.53% 0.72% -0.33% 0.13% -0.07% 1.62%
Return on Equity (ROE)
8.54% 7.21% -56.72% -8.92% 1.52% 4.33% 4.13% 2.68% 2.14% 3.78% 13.79%
Cash Return on Invested Capital (CROIC)
14.70% 12.56% 20.04% 18.84% 13.67% 8.54% 4.53% 5.68% 8.82% 25.07% 24.46%
Operating Return on Assets (OROA)
6.82% 6.86% -37.68% 3.52% 3.35% -1.09% 3.50% 0.57% 2.01% 1.18% 9.83%
Return on Assets (ROA)
4.69% 4.59% -38.71% -8.43% 2.52% -2.37% 3.04% 0.43% 0.86% 1.30% 9.60%
Return on Common Equity (ROCE)
8.54% 7.21% -56.72% -8.92% 1.52% 4.33% 4.13% 2.68% 2.14% 3.78% 13.79%
Return on Equity Simple (ROE_SIMPLE)
12.60% 7.23% -12.10% 0.00% -25.46% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
8.70 15 -98 17 1.10 5.95 3.63 6.71 4.03 7.77 22
NOPAT Margin
5.20% 8.19% -57.94% 1.95% 0.65% 3.29% 2.02% 3.41% 2.27% 4.04% 12.48%
Net Nonoperating Expense Percent (NNEP)
-0.11% -1.94% 26.12% 74.55% -3.38% 8.17% -1.74% 5.75% 1.09% 4.54% -15.20%
Return On Investment Capital (ROIC_SIMPLE)
0.62% - - 1.27% 0.08% 0.44% 0.33% 0.63% 0.39% 0.75% 2.19%
Cost of Revenue to Revenue
28.37% 24.86% 23.05% 4.49% 20.31% 22.57% 19.09% 20.47% 20.53% 22.95% 21.08%
SG&A Expenses to Revenue
43.10% 38.27% 44.10% 8.96% 51.37% 48.91% 51.14% 51.61% 52.96% 47.72% 47.46%
R&D to Revenue
10.91% 11.42% 11.33% 2.69% 15.00% 15.57% 14.46% 19.20% 15.83% 15.72% 15.10%
Operating Expenses to Revenue
63.72% 59.27% 159.71% 124.95% 78.51% 72.74% 77.36% 78.34% 75.58% 74.83% 66.32%
Earnings before Interest and Taxes (EBIT)
13 28 -140 35 6.39 -2.24 6.25 2.17 6.77 4.23 29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
32 48 -119 57 28 26 28 19 28 26 49
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.52 1.51 0.93 1.12 1.44 1.46 1.59 1.61 1.40 1.49 1.40
Price to Tangible Book Value (P/TBV)
5.23 5.09 2.24 2.47 3.36 3.51 3.57 3.65 3.26 2.72 2.38
Price to Revenue (P/Rev)
1.00 1.93 1.00 0.62 0.82 0.79 0.82 1.53 1.25 1.34 1.34
Price to Earnings (P/E)
35.89 20.94 0.00 0.00 0.00 0.00 0.00 158.29 178.10 68.20 26.47
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.79% 4.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.63% 0.56% 1.47% 3.78%
Enterprise Value to Invested Capital (EV/IC)
1.44 1.44 0.93 1.11 1.41 1.40 1.51 1.52 1.33 1.57 1.42
Enterprise Value to Revenue (EV/Rev)
1.12 2.14 1.14 0.67 0.86 0.87 0.89 1.69 1.44 1.46 1.31
Enterprise Value to EBITDA (EV/EBITDA)
9.79 8.74 55.02 50.46 82.04 0.00 9.09 12.05 10.24 10.34 7.69
Enterprise Value to EBIT (EV/EBIT)
19.53 16.05 0.00 0.00 0.00 0.00 27.98 97.43 81.70 55.95 22.98
Enterprise Value to NOPAT (EV/NOPAT)
21.21 25.35 0.00 0.00 0.00 0.00 43.59 153.11 112.46 65.92 26.64
Enterprise Value to Operating Cash Flow (EV/OCF)
8.21 7.62 3.88 4.94 6.89 9.09 8.97 8.06 7.44 5.79 5.50
Enterprise Value to Free Cash Flow (EV/FCFF)
9.42 11.06 4.09 5.17 9.28 15.05 33.23 26.15 14.48 5.53 5.22
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.58 0.67 0.78 0.75 0.73 0.77 0.52 0.54 0.56 0.54 0.41
Long-Term Debt to Equity
0.57 0.67 0.51 0.49 0.48 0.50 0.52 0.54 0.56 0.54 0.41
Financial Leverage
0.32 0.26 0.22 0.16 0.13 0.16 0.14 0.12 0.14 0.10 0.06
Leverage Ratio
1.87 1.89 1.93 1.90 1.88 1.95 1.91 1.92 1.92 1.95 1.74
Compound Leverage Factor
1.96 2.45 1.92 -2.04 2.55 1.67 2.91 0.50 1.42 1.17 1.71
Debt to Total Capital
36.84% 40.13% 43.93% 42.92% 42.22% 43.38% 34.13% 34.94% 35.99% 35.08% 29.19%
Short-Term Debt to Total Capital
0.61% 0.00% 15.07% 14.80% 14.62% 15.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
36.23% 40.13% 28.86% 28.13% 27.59% 28.25% 34.13% 34.94% 35.99% 35.08% 29.19%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
63.16% 59.87% 56.07% 57.08% 57.79% 56.62% 65.87% 65.06% 64.01% 64.92% 70.81%
Debt to EBITDA
3.36 3.48 40.85 31.59 39.50 -81.46 2.70 3.66 3.56 3.46 2.32
Net Debt to EBITDA
1.02 0.88 6.73 3.51 4.18 -16.25 0.79 1.10 1.38 0.84 -0.20
Long-Term Debt to EBITDA
3.30 3.48 26.84 20.70 25.82 -53.06 2.70 3.66 3.56 3.46 2.32
Debt to NOPAT
7.28 10.09 -12.93 -11.40 -9.85 -7.95 12.95 46.52 39.09 22.03 8.03
Net Debt to NOPAT
2.21 2.54 -2.13 -1.27 -1.04 -1.59 3.79 13.93 15.17 5.35 -0.68
Long-Term Debt to NOPAT
7.16 10.09 -8.49 -7.47 -6.44 -5.18 12.95 46.52 39.09 22.03 8.03
Altman Z-Score
2.32 1.84 0.79 1.80 1.93 1.91 2.53 1.93 1.79 1.92 2.19
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.81 6.82 2.25 2.40 2.41 2.38 5.26 4.54 4.73 5.04 4.68
Quick Ratio
4.58 5.49 1.81 1.93 1.90 1.79 3.38 3.01 3.01 3.14 3.32
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
98 90 141 249 191 160 13 46 68 188 172
Operating Cash Flow to CapEx
1,731.35% 3,348.18% 1,317.69% 1,564.31% 414.82% 445.38% 1,571.94% 20,040.83% 942.73% 4,300.90% 1,381.24%
Free Cash Flow to Firm to Interest Expense
29.61 0.00 30.14 0.00 41.68 34.13 2.41 11.70 18.30 51.84 59.61
Operating Cash Flow to Interest Expense
14.81 0.00 11.50 0.00 7.74 2.56 11.56 11.23 6.94 15.86 17.36
Operating Cash Flow Less CapEx to Interest Expense
13.95 0.00 10.63 0.00 5.88 1.98 10.83 11.17 6.21 15.50 16.10
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.87 0.43 0.45 0.90 0.89 0.88 1.01 0.52 0.53 0.54 0.59
Accounts Receivable Turnover
13.93 6.77 7.03 12.81 13.60 12.84 13.13 6.12 6.38 6.05 6.24
Inventory Turnover
1.93 1.83 1.71 1.48 1.36 1.22 1.11 1.08 1.07 1.10 1.10
Fixed Asset Turnover
7.68 3.95 4.06 8.22 8.35 8.68 9.02 4.72 4.89 5.23 5.38
Accounts Payable Turnover
13.95 8.34 9.94 9.79 9.79 6.30 8.06 8.74 8.17 6.51 8.99
Days Sales Outstanding (DSO)
26.21 53.89 51.89 28.49 26.83 28.43 27.79 59.64 57.21 60.36 58.48
Days Inventory Outstanding (DIO)
189.17 199.26 213.37 245.90 267.44 298.31 329.40 338.98 341.46 332.57 331.47
Days Payable Outstanding (DPO)
26.16 43.75 36.74 37.30 37.30 57.92 45.28 41.78 44.69 56.03 40.62
Cash Conversion Cycle (CCC)
189.22 209.41 228.53 237.09 256.97 268.82 311.92 356.83 353.99 336.90 349.33
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
1,050 1,028 846 843 860 874 837 805 797 694 687
Invested Capital Turnover
1.24 0.65 0.72 1.46 1.47 1.48 1.68 0.88 0.89 0.95 0.98
Increase / (Decrease) in Invested Capital
-89 -75 -239 -232 -190 -154 -9.07 -39 -64 -180 -150
Enterprise Value (EV)
1,517 1,480 791 935 1,212 1,222 1,268 1,225 1,058 1,087 974
Market Capitalization
1,359 1,332 694 870 1,150 1,107 1,158 1,113 915 998 999
Book Value per Share
$19.19 $18.89 $16.25 $16.86 $17.26 $16.36 $16.18 $16.11 $16.15 $17.08 $17.87
Tangible Book Value per Share
$5.59 $5.62 $6.71 $7.63 $7.39 $6.80 $7.22 $7.08 $6.94 $9.32 $10.53
Total Capital
1,412 1,469 1,337 1,364 1,382 1,338 1,104 1,065 1,022 1,035 1,006
Total Debt
520 589 587 585 583 580 377 372 368 363 294
Total Long-Term Debt
512 589 386 384 381 378 377 372 368 363 294
Net Debt
158 149 97 65 62 116 110 111 143 88 -25
Capital Expenditures (CapEx)
2.84 1.59 4.09 2.12 8.55 2.70 3.87 0.22 2.72 1.34 3.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)
132 135 131 152 154 189 209 189 204 242 169
Debt-free Net Working Capital (DFNWC)
458 540 585 637 647 635 456 427 406 493 464
Net Working Capital (NWC)
450 540 384 435 445 432 456 427 406 493 464
Net Nonoperating Expense (NNE)
-0.28 -4.31 46 101 -3.71 11 -1.80 5.07 1.11 3.12 -6.48
Net Nonoperating Obligations (NNO)
158 149 97 65 62 116 110 111 143 22 -25
Total Depreciation and Amortization (D&A)
19 20 21 22 22 28 22 17 21 22 20
Debt-free, Cash-free Net Working Capital to Revenue
9.76% 19.60% 18.88% 10.87% 10.95% 13.43% 14.77% 26.01% 27.76% 32.46% 22.68%
Debt-free Net Working Capital to Revenue
33.78% 78.16% 84.18% 45.44% 46.11% 45.13% 32.14% 58.84% 55.27% 66.10% 62.44%
Net Working Capital to Revenue
33.14% 78.16% 55.19% 31.04% 31.72% 30.74% 32.14% 58.84% 55.27% 66.10% 62.44%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.19 $0.41 ($3.11) $0.36 $0.10 ($0.11) $0.12 $0.05 $0.07 $0.12 $0.72
Adjusted Weighted Average Basic Shares Outstanding
46.50M 46.17M 46.13M 46.25M 46.28M 45.46M 44.04M 44.57M 40.46M 39.46M 39.86M
Adjusted Diluted Earnings per Share
$0.19 $0.39 ($3.11) $0.38 $0.10 ($0.11) $0.12 $0.05 $0.07 $0.12 $0.70
Adjusted Weighted Average Diluted Shares Outstanding
52.19M 50.54M 46.13M 46.25M 46.53M 45.46M 44.46M 45.04M 40.91M 40.30M 40.83M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
46.55M 46.13M 46.17M 46.28M 46.30M 44.93M 43.02M 40.49M 39.35M 39.86M 40.09M
Normalized Net Operating Profit after Tax (NOPAT)
9.95 16 15 17 4.52 6.39 7.50 1.99 4.03 2.99 22
Normalized NOPAT Margin
5.95% 8.98% 9.11% 1.95% 2.68% 3.53% 4.18% 1.01% 2.27% 1.55% 12.48%
Pre Tax Income Margin
8.16% 20.55% -82.37% -4.23% 5.15% -1.06% 5.31% 0.29% 2.82% 1.33% 16.31%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
3.94 0.00 -29.78 0.00 1.40 -0.48 1.19 0.56 1.83 1.17 10.12
NOPAT to Interest Expense
2.62 0.00 -20.83 0.00 0.24 1.27 0.69 1.72 1.09 2.15 7.64
EBIT Less CapEx to Interest Expense
3.08 0.00 -30.65 0.00 -0.47 -1.05 0.45 0.50 1.09 0.80 8.87
NOPAT Less CapEx to Interest Expense
1.77 0.00 -21.70 0.00 -1.63 0.69 -0.05 1.67 0.35 1.78 6.38
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 54.02% -37.86% -17.25% 0.00% -22.04% -130.93% 2,139.81% 3,903.44% 1,037.41% 264.03%

Financials Breakdown Chart

Key Financial Trends

Pacira BioSciences’ recent results show improving revenue and a return to profitability, although operating margins remain thin and the balance sheet has become less liquid than it was two years ago. The latest quarter, Q2 2026, included $192.4 million of revenue, up 6.2% from $181.1 million in the restated Q2 2025 and 8.1% from Q2 2024. Revenue has generally moved higher from approximately $160 million to $170 million per quarter in 2023 and early 2024.

Gross profit increased to $148.2 million in Q2 2026 from $140.2 million in Q2 2025. However, the gross margin slipped slightly to about 77.0% from 77.4%, while operating income fell to $4.3 million from $8.5 million. Higher selling, general and administrative expense, research and development spending, and other operating expenses limited operating leverage.

Net income improved to $4.7 million, or $0.12 per diluted share, compared with a restated net loss of $4.8 million, or $0.11 per share, in Q2 2025. Pacira has reported positive net income in each of the first two quarters of 2026, but earnings remain modest relative to revenue. Interest expense also continues to consume a meaningful portion of operating profit.

Cash generation was a major positive in Q2 2026. Operating cash flow reached $57.5 million, compared with $12.0 million in Q2 2025 and $53.2 million in Q2 2024. The improvement was helped by a $15.7 million favorable change in operating assets and liabilities, meaning some of the quarter’s cash benefit may reflect working-capital timing rather than a permanent improvement in earnings power.

Liquidity improved sequentially, with cash rising to $205.9 million from $144.3 million at the end of Q1 2026. Including short-term investments, Pacira held approximately $251.0 million of near-term cash and investments at June 30, 2026. That is well below the $445.9 million held at the end of Q2 2025. Long-term debt stood at $363.1 million, and Pacira paid down $5 million of debt during Q2.

  • Revenue growth is continuing: Q2 2026 revenue rose 6.2% year over year and was more than 19% above Q2 2023, indicating continued expansion of the commercial business.
  • Profitability has recovered: Pacira moved from a $4.8 million restated net loss in Q2 2025 to $4.7 million of net income in Q2 2026, with diluted EPS improving to $0.12.
  • Operating cash flow remains strong: The company generated $57.5 million of operating cash flow in Q2 2026, substantially above the prior-year quarter and enough to fund capital spending, debt repayment and limited share repurchases.
  • Debt has declined from earlier levels: Total debt was approximately $363.1 million at the end of Q2 2026, down from roughly $580.5 million in Q2 2025 and $589.3 million in Q2 2024.
  • Share count has contracted: Basic weighted-average shares fell to 39.5 million in Q2 2026 from 45.5 million in Q2 2025, supported by prior repurchases. A lower share count can increase per-share value when earnings improve.
  • Working capital is volatile: Accounts receivable increased year over year while inventory declined to $134.6 million from $148.2 million. These movements helped or hurt quarterly cash flow at different points and should be monitored for normalization.
  • Investment activity is affecting reported cash balances: Q2 2026 investing cash flow was positive $11.8 million primarily because the company sold or received maturities on $17.0 million of investments. This is useful for liquidity, but it is not recurring operating revenue.
  • Operating margins remain narrow: Q2 2026 operating income represented only about 2.2% of revenue, down from approximately 4.7% in Q2 2025, despite higher sales.
  • Expenses continue to pressure earnings: SG&A was $91.8 million and R&D was $30.2 million in Q2 2026. Together, these expenses consumed more than 63% of revenue before amortization and other operating costs.
  • Liquidity is lower than a year ago: Cash and short-term investments declined by approximately $195 million from Q2 2025, while Pacira still carries more debt than its cash and short-term investment balances alone.

Overall, the statements point to a company with growing revenue, positive operating cash flow and reduced leverage, but with limited operating profitability. Investors should focus on whether Pacira can convert its recent revenue gains and strong cash generation into sustainably higher operating margins while rebuilding liquidity. Several historical figures are marked as restated or calculated, and some older quarterly data contain unusual classification differences, so year-over-year comparisons should be interpreted with caution.

11/17/26 02:12 AM ETAI Generated. May Contain Errors.

Pacira BioSciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Pacira BioSciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Pacira BioSciences' net income appears to be on an upward trend, with a most recent value of $7.03 million in 2025, rising from $1.86 million in 2015. The previous period was -$99.56 million in 2024. View Pacira BioSciences' forecast to see where analysts expect Pacira BioSciences to go next.

Pacira BioSciences' total operating income in 2025 was $19.19 million, based on the following breakdown:
  • Total Gross Profit: $576.66 million
  • Total Operating Expenses: $557.47 million

Over the last 10 years, Pacira BioSciences' total revenue changed from $249.00 million in 2015 to $726.41 million in 2025, a change of 191.7%.

In the past 13 quarters, Pacira BioSciences' cash and equivalents has ranged from $86.81 million in Q2 2023 to $300.48 million in Q2 2025, and is currently $246.96 million as of their latest financial filing in Q3 2026.

Pacira BioSciences had total debt of $372.19 million at the end of 2025, a 36.4% decrease from 2024, and a 257.7% increase since 2015.

Over the last 10 years, Pacira BioSciences' book value per share changed from 5.94 in 2015 to 16.11 in 2025, a change of 171.2%.



Financial statements for NASDAQ:PCRX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners